ArticleFrontiers in medicine2026
Increase in serum prolactin levels as a potential biomarker in Crohn's disease: a prospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease (CD) management lacks biomarkers that precisely reflect immune activity. Prolactin (PRL) has immunomodulatory functions, but its role in CD is unclear. Aim: To investigate serum PRL changes in CD patients and evaluate its potential as a biomarker for disease activity and treatment response. Methods: In a prospective cohort study, serum PRL levels were analyzed in 185 CD patients and 58 healthy controls, and correlated with clinical markers (CRP, FC). Results: Serum PRL levels were significantly higher in CD patients versus controls (p<0.001). Higher baseline PRL levels correlated with a greater reduction in CRP after treatment. The study population had no previous reproductive history. Conclusion: Elevated serum PRL may serve as a supplementary biomarker reflecting immune dysregulation and disease activity in CD, particularly in this cohort enriched with severe, perianal-dominant disease. Its role in evaluating therapeutic effectiveness warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.